Learn how it all started with a 1999 Munich Business Plan Competition, which gave birth to the idea of commercialized, special microcopy chambers for the cultivation and visualization of cells. In 2001, a new company, ibidi, was spun off from the Technische Universität Munich (TUM) and the Center for Nanoscience (CENS) of the Ludwig-Maximilians-Universität Munich (LMU).

Today, ibidi is a medium-sized company with: headquarters in Munich (Germany) and Madison, Wisconsin (USA), a strong network of global distribution partners, over 500 products, and more than 40,000 customers worldwide. Within two decades, ibidi has succeeded in becoming the world’s leading provider of products for cell-based microscopy assays.

"It is our mission to provide scientists with tools that facilitate their daily research routine by enabling the standardization and reproducibility of experiments," explains Dr. Roman Zantl, Founder, CEO, and Head of Research & Development. "Thus, we contribute to a better understanding of the underlying mechanisms of cancer and cardiovascular and autoimmune diseases, which can lead to the development of effective therapies."

New innovations that help advance biomedical research will continue to be the focus of ibidi going into the future. In 2021, ibidi plans to launch their Micropatterning product family, which has a breakthrough technology that enables the spatially precise attachment of cells to slides and microscopy chambers for various cell-based applications in 2D and 3D. In addition, ibidi is involved in numerous pioneering research projects, including 3D cell culture and bioprinting. These types of collaborative efforts promote the cooperation between university research groups and industry, in order to continue translating scientific discoveries into creative products.